The therapy of ALK-positive or ROS1-positive NSCLC has evolved greatly in recent years with the availability of various ALK or ROS1 inhibitors. This CME will summarize and discuss the current ESMO guidelines and key trial data.
Autoren
- Dr. med. Hasna Bouchaab
- Dr. med. Dr. rer. nat. Christian Britschgi
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- PancNEN, PancNET & PancNEC
Neuroendocrine tumors of the pancreas
- Heart failure
Interventional treatment of the tricuspid valve
- Lipoprotein(a)
Current and future treatment options
- Lichen sclerosus
Topical corticosteroids still the first choice
- Breast Cancer
On the trail of triple-negative breast cancer
- Headache treatment
The therapy of migraine
- Sleep disorders in old age
Recognize insomnia, treat it and avoid cognition disorders
- From symptom to diagnosis